63E.F ONWARD MEDICAL BV EO -12
- Market cap
- EUR 119M
- P/E
- -
- P/B
- 1.69x
- ROE
- -75.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 63E.F undervalued?
Graham numberThe Graham number of ONWARD MEDICAL BV EO -12 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ONWARD MEDICAL BV EO -12 fundamental analysis
No fundamental analysis for ONWARD MEDICAL BV EO -12 yet.
ONWARD MEDICAL BV EO -12 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implan…
Full company profileONWARD MEDICAL BV EO -12 financial statements
ONWARD MEDICAL BV EO -12 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 104K | 68.0K | 229K | 3.78M |
| Gross Profit | -12.0M | -14.7M | 68.0K | 207K | 2.74M |
| Operating Income | -28.5M | -32.0M | -35.5M | -34.9M | -40.9M |
| EBITDA | - | -31.3M | -34.0M | -32.9M | -37.8M |
| Net Income | -34.3M | -32.8M | -36.2M | -35.7M | -41.8M |
| EPS | -1.14 | -1.09 | -1.20 | -0.80 | -0.75 |
| Balance Sheet | |||||
| Total Assets | 105M | 76.6M | 43.6M | 76.1M | 84.6M |
| Total Liabilities | 22.1M | 24.0M | 25.7M | 28.1M | 29.2M |
| Shareholders' Equity | 82.7M | 52.6M | 17.9M | 48.1M | 55.3M |
| Cash & Short-term Investments | 89.4M | 41.8M | 29.8M | 60.0M | 68.1M |
| Cash Flow | |||||
| Operating Cash Flow | -19.9M | -26.7M | -32.3M | -31.8M | -39.1M |
| Capital Expenditure | 2.32M | 417K | 422K | 150K | 432K |
| Free Cash Flow | -22.2M | -27.1M | -32.7M | -31.9M | -39.5M |
| Ratios | |||||
| ROE | -41.5% | -62.3% | -201.8% | -74.3% | -75.5% |
| ROA | -32.7% | -42.8% | -82.9% | -46.9% | -49.4% |
| Net Profit Margin | - | -31,511.5% | -53,207.4% | -15,600.4% | -1,105.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ONWARD MEDICAL BV EO -12 dividends
ONWARD MEDICAL BV EO -12 has not paid dividends in the last 5 fiscal years.
Who owns ONWARD MEDICAL BV EO -12
- Insiders 27.05%
- Institutions 23.41%
- Public & others 49.54%
- Shares outstanding 69.5M
- Free float 54.7M
ONWARD MEDICAL BV EO -12 company profile
- Company name
- ONWARD MEDICAL BV EO -12
- Ticker
- 63E.F
- ISIN
- NL0015000HT4
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 137
- Fiscal year end
- December
- Address
- Schimmelt 2, Eindhoven, Netherlands, NL-5611
- Website
- onwd.com
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implantable system currently being investigated to enable thought driven movement of the legs and upper extremities. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
ONWARD MEDICAL BV EO -12 management
10- Mr. David L. MarverCEO & Executive Director · born 1968
- Dr. Gregoire Courtine Ph.D.Co-Founder & Senior Advisor · born 1975
- Mr. Ali KiboroChief Financial Officer · born 1976
- Mr. Robert W. OdellVice President of Operations · born 1960
- Mr. Lorenzo FantiVice President of Legal
- Mr. Sebastien CrosVice President of Communications
- Mr. Alexandre CasteauHead of Strategy & Corporate Development
- Ms. Julie CromDirector of People & Culture
- Mr. Sean SciaraChief Commercial Officer
- Ms. Shari O'QuinnChief Clinical, Regulatory & Quality Officer